Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other neoplasm 1

Conditions

Precancerous Conditions 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1

Interventions

Peripheral Blood Stem Cell Transplantation 7Cyclophosphamide 7fludarabine phosphate 6Whole-Body Irradiation 5Epoetin Alfa 5Tacrolimus 4Mycophenolic Acid 4Cyclosporine 4Busulfan 4Antilymphocyte Serum 4Methotrexate 3Etoposide 3Darbepoetin alfa 3Sirolimus 2Morphine 2Methylprednisolone 2Melphalan 2Interferon-alpha 2Filgrastim 2Cytogenetic Analysis 2Carboplatin 2sargramostim 1pyroxamide 1ferrous sulfate 1ferric gluconate 1alethine 1aldesleukin 1Topotecan 1Therapeutics 1Tetradecanoylphorbol Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precancerous Conditions × alethine × Plasma cell × Clear all
NCT00006466 2013-12-18

Beta Alethine in Treating Patients With Myeloma

National Cancer Institute (NCI)

Phase 1/2 Unknown
Other neoplasmPlasma cell

Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Precancerous Conditions, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡